Weleader Biomedical CoROCO:7713 47 FCF Yield % is 3.11 as of Jul. 06, 2026, which is 14% above its 10-year median of 2.74. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 71.61% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Weleader Biomedical Co's FCF Yield % or its related term are showing as below:
ROCO:7713'
s FCF Yield % Range Over the Past 10 Years
Min: -0.05 Med: 2.74 Max: 5.01
Current: 3.11
During the past 6 years, the highest FCF Yield % of Weleader Biomedical Co was 5.01%. The lowest was -0.05%. And the median was 2.74%.
ROCO:7713's FCF Yield % is ranked better than 71.61% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: -0.39
vs ROCO:7713: 3.11
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Weleader Biomedical Co FCF Yield % Related Terms
Weleader Biomedical Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7713 vs ABT, SYK, MDT: FCF Yield % Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a FCF Yield % of 3.11 as of Jul. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Weleader Biomedical Co and its competitors. This is 14% above median its historical median of 2.74. According to the industry distribution chart, Weleader Biomedical Co ranks #243 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is Weleader Biomedical Co's FCF Yield % too high?
Weleader Biomedical Co's current FCF Yield % of 3.11 is 14% above median its 10-year median of 2.74. Based on the distribution chart, Weleader Biomedical Co ranks #243 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #243 out of 856 companies for FCF Yield %. This puts Weleader Biomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current FCF Yield % is 3.11, which is 14% above median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current FCF Yield % of 3.11. The current FCF Yield % is 3.11, which is 14% above median its 10-year median of 2.74. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current FCF Yield % is 3.11 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score
Get the complete analysis for ROCO:7713
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
